DR REDDYS LABORATORIES
|
DR REDDYS LABORATORIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 334.41 | 270.55 | 131.16 | 117.28 | 121.90 |
| CEPS(Rs) | 422.54 | 345.59 | 201.18 | 191.13 | 191.88 |
| DPS(Rs) | 40.00 | 40.00 | 30.00 | 25.00 | 25.00 |
| Book NAV/Share(Rs) | 1,686.06 | 1,388.98 | 1,145.98 | 1,052.59 | 932.31 |
| Tax Rate(%) | 22.54 | 25.48 | 28.71 | 32.32 | -7.44 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 28.32 | 25.74 | 17.49 | 20.32 | 14.10 |
| EBIT Margin(%) | 26.32 | 25.10 | 14.65 | 15.65 | 11.33 |
| Pre Tax Margin(%) | 25.71 | 24.52 | 14.21 | 15.14 | 10.76 |
| PAT Margin (%) | 19.91 | 18.27 | 10.13 | 10.25 | 11.57 |
| Cash Profit Margin (%) | 25.16 | 23.34 | 15.54 | 16.70 | 18.21 |
| Performance Ratios | |||||
| ROA(%) | 16.08 | 15.01 | 8.08 | 8.21 | 9.20 |
| ROE(%) | 21.76 | 21.36 | 11.93 | 11.82 | 13.76 |
| ROCE(%) | 26.86 | 26.22 | 14.59 | 15.49 | 11.12 |
| Asset Turnover(x) | 0.81 | 0.82 | 0.80 | 0.80 | 0.80 |
| Sales/Fixed Asset(x) | 1.04 | 1.01 | 0.96 | 0.92 | 0.94 |
| Working Capital/Sales(x) | 1.84 | 2.10 | 2.69 | 2.96 | 3.25 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.96 | 0.99 | 1.04 | 1.08 | 1.07 |
| Receivable days | 99.54 | 103.01 | 98.60 | 95.74 | 93.92 |
| Inventory Days | 73.12 | 73.65 | 81.57 | 77.11 | 71.52 |
| Payable days | 108.56 | 108.07 | 99.98 | 100.14 | 95.02 |
| Valuation Parameters | |||||
| PER(x) | 18.41 | 17.08 | 32.83 | 38.50 | 25.57 |
| PCE(x) | 14.57 | 13.37 | 21.40 | 23.63 | 16.24 |
| Price/Book(x) | 3.65 | 3.33 | 3.76 | 4.29 | 3.34 |
| Yield(%) | 0.65 | 0.87 | 0.70 | 0.55 | 0.80 |
| EV/Net Sales(x) | 3.68 | 3.11 | 3.37 | 3.99 | 3.07 |
| EV/Core EBITDA(x) | 11.66 | 10.35 | 17.08 | 18.29 | 17.41 |
| EV/EBIT(x) | 13.96 | 12.37 | 23.00 | 25.53 | 27.12 |
| EV/CE(x) | 3.40 | 3.11 | 2.55 | 2.98 | 2.45 |
| M Cap / Sales | 3.67 | 3.12 | 3.33 | 3.94 | 2.96 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 13.54 | 14.50 | 13.11 | 8.74 | 13.39 |
| Core EBITDA Growth(%) | 19.22 | 74.14 | 2.18 | 34.63 | -12.08 |
| EBIT Growth(%) | 19.07 | 96.10 | 5.93 | 50.23 | -18.18 |
| PAT Growth(%) | 23.75 | 106.52 | 11.83 | -3.67 | 3.90 |
| EPS Growth(%) | 23.60 | 106.27 | 11.83 | -3.79 | 3.77 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.07 | 0.06 | 0.18 | 0.17 | 0.14 |
| Current Ratio(x) | 2.59 | 2.37 | 1.82 | 1.79 | 1.75 |
| Quick Ratio(x) | 1.92 | 1.80 | 1.30 | 1.23 | 1.26 |
| Interest Cover(x) | 43.09 | 43.36 | 32.96 | 30.73 | 20.18 |
| Total Debt/Mcap(x) | 0.02 | 0.02 | 0.05 | 0.04 | 0.04 |
Compare Financial Ratios of peers of DR REDDYS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DR REDDYS LABORATORIES | ₹110,174.9 Cr | -0.1% | -0.2% | 19.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,342.0 Cr | -0.2% | 3% | 68% | Stock Analytics | |
| DIVIS LABORATORIES | ₹163,028.0 Cr | 13.7% | 12.9% | 60.4% | Stock Analytics | |
| CIPLA | ₹128,832.0 Cr | -1.8% | -2% | 39.6% | Stock Analytics | |
| MANKIND PHARMA | ₹111,956.0 Cr | 9.2% | 14.8% | 51.3% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹107,214.0 Cr | 1.4% | -4.2% | 76% | Stock Analytics | |
DR REDDYS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DR REDDYS LABORATORIES | -0.1% |
-0.2% |
19.8% |
| SENSEX | -0.4% |
-0.7% |
23.3% |
You may also like the below Video Courses
